Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Carfilzomib +/- Rituximab in WM and MZL
NCT03269552Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Dec 2017
- Primary completion
- Dec 2018
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), sponsored by University of Washington. Started Dec 2017; status: terminated.
02
Drugs
carfilzomib
03
Conditions
Waldenström's macroglobulinemia (WM)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT03269552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03269552.